Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach.

Current neurology and neuroscience reports - 1 Apr 2023

Menozzi Elisa, Schapira Anthony H V, Blandini Fabio, Avenali Micol

Abstract excerpt

PURPOSE OF REVIEW: Genetic variants in GBA1 and LRRK2 genes are the commonest genetic risk factor for Parkinson disease (PD); however, the preclinical profile of GBA1 and LRRK2 variant carriers who will develop PD is unclear. This review aims to highlight the more sensitive markers that can stratify PD risk in non-manifesting GBA1 and LRRK2 variant carriers. RECENT FINDINGS: Several case-control and a few...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glucosylceramidase
Share to Heterozygote

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Leukocytes, Mononuclear

Share to Longitudinal Studies

Share to Mutation

Share to Parkinson Disease

Share to Prodromal Symptoms

Source

Open in PubMed Open full text

Identifiers

PMID: 36881256
DOI: 10.1007/s11910-023-01259-1
PMCID: PMC10119235

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach.PMID 36881256Read ↗

Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease.Semantic proximity Read ↗

Exploring the Genotype–Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential ModifiersSemantic proximity Read ↗

GBA-associated PD: chances and obstacles for targeted treatment strategies.Semantic proximity Read ↗

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.Semantic proximity Read ↗

Genetic Forms of Parkinson's Disease.Semantic proximity Read ↗

Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson diseaseSemantic proximity Read ↗

Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.Semantic proximity Read ↗

Multi-omics insights into GBA1-associated Parkinson's disease: interplay of genomics, transcriptomics, proteomics, and lipidomics.Semantic proximity Read ↗

Features of GBA-associated Parkinson's disease at presentation in the UK Tracking Parkinson's study.Semantic proximity Read ↗

From disease to syndrome: the evolution of Parkinson's as a heterogeneous entity.Semantic proximity Read ↗

Parkinson's Disease: From Gene-Environment Risk to Precision Therapy.Semantic proximity Read ↗

Imaging and genetics in Parkinson's disease: assessment of the GBA1 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.